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Background: The association between homocysteine (Hcy) and metabolic syndrome (MetS)-related dis-
orders remains to be unveiled. First, the role of Hcy–MetS interaction in prediction of coronary heart
disease (CHD) was assessed. Next, we investigated whether serum Hcy improves CHD risk-prediction
beyond MetS and traditional risk factors (TRFs).
Design: A prospective study of 5893 community-dwelling participants (two sub-cohorts, 3286 diabetic
and 2607 non-diabetic; ∼8.5 years of follow-up).
Methods: Clustering of Hcy with MetS components was assessed using exploratory factor-analysis. Cox
regression hazard ratio (HR) was used to predict CHD using Hcy level and MetS status. Baseline model
included MetS and TRFs. Addition of Hcy and hyper-homocysteinemia (HHcy) to the baseline model was
evaluated in two separate models.iomarkers Results: Hcy was correlated with MetS components, especially with systolic blood pressure. The factor
linking MetS to CHD is the factor through which Hcy is linked to MetS. HHcy and MetS interacted as risk
factors for CHD.
Conclusion: Hcy adds to the value of MetS and TRFs for CHD risk-prediction by reclassifying around
47.3–49.0% of the overall and 21.6–28.1% of the intermediate-risk population.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
Coronary heart disease (CHD) is among the leading causes of
ortality worldwide [1]. Traditional risk factors (TRFs) contribut-
ng to a CHD event have been recognized [2]. Preventive strategies
ltering these modiﬁable risk factors can play a major role in con-
rolling the incident cases [3]. Prediction of susceptible or at-risk
ubjects is the prior step to any preventive program. Scoring sys-
ems predicting the risk of CHD in prospective time frames have
een designed [4,5]. Despite predictive strategies, a great number
f cases remain unpredicted [3].Moreover, among the at-risk strat-
ﬁedpopulation, amajority fall into the intermediate-risk group, for
hom the clinical decision remains controversial [6]. Novel strate-
ies aremandated tounveil indeterminate cases and to enhance the
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EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sci-
nces, P.O. Box 13145-784, Tehran, Iran. Tel.: +98 21 88417918;
ax: +98 21 64432466.
E-mail address: esteghamati@tums.ac.ir (A. Esteghamati).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.001
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reprecision of CHD risk-prediction models that rely on conventional
risk factors [7].
Novel markers have been introduced in recent decades which
can either anticipate or be associated with an incident CHD event
[8]. C-reactive protein, B-type natriuretic peptide, lipoprotein
(a), and homocysteine (Hcy) are to name a few [9]. Hcy is a
non-essential amino acid that is known as a marker of endothelial
injury [10]. Hyper-homocysteinemia (HHcy) is regarded as a
risk factor for development of atherosclerotic vascular injuries
including CHD [11].
Metabolic syndrome (MetS) is an entity that clusters a number
of metabolic abnormalities, including abdominal obesity, impaired
glucose metabolism, dyslipidemia, and hypertension [12]. MetS
and its components have been strongly correlated to CHDandother
thrombotic events [13]. Control of MetS can be the mainstay of
preventive programs [14].
MetS components and Hcy have both been subjects of studies
focused on CHD prevention [14–16]. Nonetheless, the existing
relationship between them is a contentious issue in the literature
[17–19]. Debates on whether they share a common linkage or
not persists [17]. It seems appealing to indicate if Hcy is part of
served.
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etS-related disorders and if MetS components and Hcy interact
n an incident CHD event.
The purpose of this study was to investigate the association
etween Hcy and MetS components, and to reveal their clustering
attern. Next, we assessed whether Hcy improves CHD risk pre-
iction beyond MetS and TRFs. Finally, the extent by which Hcy
easurement couldassist in thepredictionandpreventionof aCHD
vent, beyond the capability of MetS and the TRFs, was estimated.
aterials and methods
tudy population
This study uses the data from an Iranian prospective open
ohort. Organized subject recruitment for research purposes
tarted in 2005. Strategic preparations of the structure were per-
ormed in the years before 2005. The primary aim of the study was
o investigate the natural history and the outcome of MetS and its
orrelates. Participants were at least 15 years old (by the time of
nquiry) and were randomly selected with the aid of four local pri-
ary health surveillance centers located in the center, east, west,
nd south of Tehran. Details on the recruitments and extrapola-
ion of the data to the Tehran general population are as previously
escribed [12]. Multiple cross-sectional studies revealed charac-
eristics of the study population from 2006 to 2012 [12,20–22].
he original cohort consists of two sub-cohorts of healthy, commu-
ity dwelling participants with and without diabetes. The diabetic
ub-cohort consisted of subjects who were newly diagnosed with
iabetes in their entry workup. All subjects were investigated prior
o their inclusion and those with recognized benign or malignant
athologies of internal organswere not included. Details on exami-
ations and included individualswere as previously described [12].
verall, 5893 subjects with available follow-ups until fall 2013
ere included in the study. Missing values accounted for 3.4% of
he values. Model-based expectation maximization method was
sed in handling the missing data. Hcy’s main effect was conﬁrmed
o be similar to the obtained results from complete case analysis
nd multiple imputations. The study protocol was approved by the
nstitutional review board of the Endocrinology and Metabolism
esearch Center, Tehran University of Medical Sciences. All partic-
pants provided informed consent on their entry.
easurements and laboratory tests
Individuals’ demographics including age, gender, and medi-
ations were recorded by history taking. Weights and heights
ere measured in light clothing and without shoes. Waist cir-
umference was measured in the middle point of iliac crest and
ib cage. After resting in supine position for 10min, systolic and
iastolic blood pressures were measured twice with a 15-min
nterval. The average of these measurements was used for the
nalysis. After 12h overnight fasting, blood samples were col-
ected for laboratory testing. Fasting plasma glucose (FPG) and 2-h
ost-prandial plasma glucose levels were assayed by glucose oxi-
ase method. Lipid proﬁle including total cholesterol, triglycerides
TGs), low-density lipoprotein cholesterol (LDL-C), and high-
ensity lipoprotein cholesterol (HDL-C) were measured by direct
nzymatic method (Parsazmun, Karaj, Iran). Fasting insulin levels
ere assessed by radioimmunoassay (the antibody had no cross-
eactivity with pro-insulin and C-peptide; Immunotech, Prague,
zech Republic). C-peptide was measured by radioimmunoassay
Immunotech), and serum creatinine level was determined by the
affe method (Parsazmun). Hemoglobin A1c was determined using
igh performance liquid chromatography (HPLC; DS5 Pink kit;
rew, Marseille, France). Hcy level was measured using HPLC by
ur designated laboratory.rdiology 64 (2014) 290–296 291
Deﬁnitions and outcome measures
For the current study, ﬁrst CHD was set as the primary out-
come; deﬁnitions and ascertainments were done according to
established protocols [23] and our previous investigations [20,22].
CHD was deﬁned as evident episodes of myocardial infarction,
angina pectoris, coronary insufﬁciency, or CHD death. All events
were adjudicated by our center’s physicians. All subjects were
scheduled to be visited every 3 months. Trained research assis-
tants completed the follow-up visits in case of missed visits. Date
of each event was recorded. In non-event cases, date of the last
visit was recorded. Data updates are performed annually. Cigarette
smoking was deﬁned by self-reported use of cigarettes in the
year preceding the entry. Diabetes was deﬁned according to the
American Diabetes Association guidelines [24]. Diabetic subjects
began initial treatment with metformin, glibenclamide, or both.
Subjects requiring use of insulin for glycemic control at the time
of diagnosis as well as subjects diagnosed with type I diabetes
mellitus or pancreatitis-related diabetes, were not included in the
cohort. Body mass index (BMI) was computed using the weight
(kg)/height2 (m) equation. The homeostasis model assessment-
insulin resistance (HOMA-IR) index indicating insulin resistance
was estimated as FPG (mg/dL)× fasting insulin (U/L)/405. Accord-
ing to the nationally modiﬁed version of the International Diabetes
Federation criteria [12], patientswith abdominal obesity (waist cir-
cumference ≥90 cm in both genders) along with any two or more
of the following were considered to have MetS: FPG≥100mg/dL
or previously diagnosed diabetes; elevated blood pressure [systolic
blood pressure (SBP)≥130mmHg and/or diastolic blood pressure
(DBP)≥85mmHg]; TG≥150mg/dL; low HDL-C levels (<50mg/dL
in females and <40mg/dL in males).
Statistical analysis
One-way ANOVA was used to describe the baseline character-
istics of the study population. A p-value for trend was derived
to compare each variable in consecutive Hcy levels (<10M/L,
10–15M/L, and ≥15M/L).
Clustering of Hcy with MetS components
Correlation of MetS components with Hcy was assessed using
Pearson bivariate correlation analysis. An exploratory factor anal-
ysis was performed to extract the principal components of MetS,
with and without addition of Hcy. The choice of MetS components
was based on a number of previous studies [12,25]. Waist cir-
cumference, HOMA-IR, TG, HDL-C, and SBP were chosen as MetS
components. Factors with an eigenvalue≥1 were included as prin-
cipal components. Components with a factor loading of >0.40 were
considered to be signiﬁcantly enrolled on the corresponding factor.
A Varimax rotation was applied. Receiver operating characteristic
(ROC) curve demonstrated the prediction of CHD by each factor.
Area under the curve (AUC) was used to compare the derived fac-
tors.
Prediction and reclassiﬁcation of CHD risk
Analysis of the CHD-free survival was performed using Cox
regressionanalysis. Theassumptionsofproportionalitywere tested
using Shoenfeld residuals. TRFs other than MetS components were
considered as possible confounders including age, sex, BMI, smok-
ing, LDL-C, family history of CHD, and therapeutic interventions
[2]. Therapeutic interventions including the use of lipid-lowering
agents were coded as nominal variables, similar to the Framing-
ham risk score for prediction of 30-year risk of cardiovascular
disease [26]. The baseline model was considered to include MetS
and TRFs for CHD. Afterwards, Hcy and HHcy were added in two
separate models, to investigate whether they add a signiﬁcant
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azard to the full model. Calibration of each model was assessed
sing Hosmer–Lemeshow’s 2 statistics, which evaluates the cor-
espondence between model predictions and actual observations.
ntrusions of the null hypothesis (p<0.01, 2 > 20) are in means of
ack of calibration. Global goodness-of-ﬁt was evaluated for each
odel using Akaike and Bayesian Information Criterion [27]. These
easures of model entropy evaluate the likelihood of a model
gainst its complexity. Likelihood ratio test compares a model’s
lobal ﬁt before and after the addition of Hcy and HHcy [27].
o evaluate the discriminatory power of models before and after
ddition of Hcy and HHcy, we used ROC curve and AUC statistics.
ue to drawbacks of AUC in detecting the incremental value of
n additional marker, newer methods were used including inte-
rated discrimination improvement (IDI) and net reclassiﬁcation
mprovement (NRI) [28]. Two main considerations were taken into
ccount to control for the inﬂation of type I error due to multiple
esting. First, a p-value less than 0.1% was adopted as the statis-
ical signiﬁcance threshold. Moreover, where applicable, we used
onferroni adjustments formultiple comparisons toavoid the inﬂa-
ion of type I error caused by multiple comparisons. Analyses were
erformed using SPSS Software v.18 (Chicago, IL, USA) and STATA
oftware, v.12 (College Station, TX, USA).esults
The mean follow-up time was 8.8 years; approximating for a
aximum of more than 45,000 person-years of follow-up. First
able 1
aseline characteristics of the study cohort across homocysteine categories.
Homocysteine (M/L)
<10 (N=2804)
Age (years) 39.2±12.2
Male (%) 16
Waist circumference (cm) 90.8±12.4
Abdominal obesity (%) 52.7
Fasting plasma glucose (mg/dL) 112.5±50.6
Impaired fasting glucose (%) 40.1
Insulin (U/mL) 9.67±6.46
HOMA-IR 2.66±2.08
Triglyceride (mg/dL) 139.3±83.6
Triglyceride≥150 (%) 33.3
HDL-C (mg/dL) 50.8±12.5
Low HDL-C (%) 47.9
Systolic blood pressure (mmHg) 114.0±15.2
Diastolic blood pressure (mmHg) 76.4±16.5
Elevated blood pressure (%) 18.7
Body mass index (kg/m2) 28.8±6.1
LDL-C (mg/dL) 112.3±32.5
Total cholesterol (mg/dL) 192.1±40.5
Creatinine (mg/dL) 0.90±0.15
Smoking (%) 17.3
Family history of CHD (%) 29.0
MetS, modiﬁed IDF (%) 30.0
OMA-IR, homeostasis model assessment-insulin resistance; HDL-C, high-density lipopr
isease; MetS, metabolic syndrome; IDF, International Diabetes Federation.
* p-Value <0.001.
able 2
orrelation matrix of metabolic syndrome components and homocysteine.
Variable Waist circumference HOMA-I
Non-diabetics
HOMA-IR 0.410
TG 0.261 0.282
HDL-C −0.195 −0.175
SBP 0.316 0.180
Homocysteine 0.273 0.125
ll p-values are <0.001.
OMA-IR, homeostasis model assessment-insulin resistance; TG, triglyceride; HDL-C, higrdiology 64 (2014) 290–296
CHD was documented in 523 cases including 318 hard events.
Among non-diabetic subjects, the ﬁrst event was angina pectoris
in 205 (39.2%), coronary insufﬁciency (documented by angiogra-
phy) in 159 (30.4%), and myocardial infarction or CHD death in
159 (30.4%) subjects. The metabolic proﬁle of the included sub-
jects had a worsening trend across the Hcy subgroups. Subjects
with higher levels of Hcy were more likely to fulﬁll a MetS cri-
terion including abdominal obesity, impaired glucose tolerance,
hypertriglyceridemia, and elevated blood pressure (Table 1).
Clustering of Hcy with MetS components
Hcy was correlated with MetS components. SBP was the
strongest correlate (r=0.293, p<0.001) (Table 2). One principal
component was extracted for MetS components to explain the
whole entity (Table 3). When Hcy values were added to the MetS
components, a second factor consisting of Hcy, SBP, and waist cir-
cumference appeared and increased the total explained variance
(39.42–53.24% without and with Hcy, respectively). Hcy clustered
with MetS components through SBP (Fig. 1). The factor which Hcy
was loaded on, predicted CHD more precisely (Fig. 2).
Prediction and reclassiﬁcation of CHD riskWhen adjusted by TRFs, MetS was still associated with a hazard
ratio (HR) of 1.76 (1.42–2.18). In categorical modeling, presence
of HHcy was associated with a HR of 3.62 (2.38–5.50), which was
10–15 (N=2960) ≥15 (N=129)
54.6±11.3 57.1±11.5*
45 58*
99.4±11.5 101.6±14.0*
81.8 83.7*
135.2±51.7 141.8±55.1*
74.2 84.5*
10.47±7.31 10.85±6.97*
3.45±2.69 3.89±3.34*
180.7±114.5 177.2±94.9*
53.4 51.2*
46.1±11.5 46.9±19.0*
54.8 55.0*
127.1±16.8 128.9±15.2*
80.2±8.4 80.5±7.2*
49.5 54.3*
29.5±5.0 29.5±4.9*
114.0±35.6 119.7±121.5
194.9±42.6 189.3±46.0
1.00±0.22 1.20±1.13*
17.3 18.6
34.0 29.0
65.1 75.2*
otein cholesterol; LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart
R TG HDL-C SBP
−0.301
0.180 −0.060
0.135 −0.166 0.293
h-density lipoprotein cholesterol; SBP, systolic blood pressure.
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Table 3
Factor loadings of MetS components and prediction of coronary heart disease; with and without addition of homocysteine.
Variable MetS components MetS components +homocysteine
Factor 1 Factor 1 Factor 2
Waist circumference 0.738a 0.446a 0.594a
HOMA-IR 0.689a 0.588a 0.304
TG 0.652a 0.735a 0.107
HDL-C −0.506a −0.729a 0.056
SBP 0.520a 0.021 0.789a
Homocysteine NA 0.065 0.701a
Explained variance (%) 39.42 27.02 26.22
AUC 0.672 (0.652–0.693) 0.561 (0.536–0.587) 0.744 (0.724–0.763)
Total explained variance (%) 39.42 NA 53.24
Factors with an eigenvalue ≥1 were selected for analysis. Factor loadings are calculated after Varimax rotation with Kaiser normalization of variables in each extracted factor.
All p-values are <0.001.
MetS, metabolic syndrome; HOMA-IR, homeostasis model assessment-insulin resistance; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood
pressure; AUC, area under the curve.
a Factor loadings≥ |0.40|.
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Mig. 1. Components plot in rotated space. HOMA-IR, homeostasis model
ssessment-insulin resistance; HDL, high-density lipoprotein.
ndependent from MetS and TRFs. In continuous modeling every
ne-unit increase in Hcy level was associated with 7% increase
n the risk of CHD (Table 4). Results of the analyses for outcome
ubtypes held similar results as for all events. By considering hard
vents as the outcome of interest, every one-unit increase in serum
cy had an effect size (HR) of 1.07 (1.05–1.09) while HHcy was
ssociated with HR of 1.37 (0.98–1.90) and 3.42 (2.15–5.44) for the
alues greater than 10 and 15M/L, in the fully adjusted model,
espectively.
Table 5 displays the summary of the statistics evaluating prop-
rties of adding Hcy and HHcy to MetS and TRFs. All three models
ad acceptable calibrations. Addition of HHcy and Hcy increased
he concordance between the predictions of the model and the
ctual observation (decreasedHosmer–Lemeshow2 statistics). By
able 4
ncidence estimates of MetS and Hcy for the ﬁrst coronary heart disease.
Variable Adjusted MetS (baseline model)
MetS 1.76 (1.42–2.18)*
Hcy≥10 NA
Hcy≥15 NA
Hcy (per 1M/L) NA
alues are hazard ratios (95% conﬁdence interval) from Cox proportional hazard analysis
holesterol, smoking, family history of coronary heart disease, interventions and drugs.
etS, metabolic syndrome; Hcy, homocysteine; HHcy, hyper-homocysteinemia. NA, not
* p<0.001.Fig. 2. Receiver operating characteristic curve statistics comparing principal com-
ponents of metabolic syndrome (MetS) with and without homocysteine (Hcy).
adding HHcy, the global ﬁt increased and the information criteria
measuring the model entropy decreased signiﬁcantly (likelihood
ratio test,p-value <0.05). All baselinemodels hadAUC ranging from
0.853 to 0.858. The incremental AUC after addition of Hcy was >1
for HHcy. IDI was also greater for Hcy, in comparison with HHcy.
Addition of HHcy and Hcy successfully reclassiﬁed 47.3% and 49.0%
of the whole population, respectively. However, intermediate-risk
groups were reclassiﬁed in approximately 21.6–28.1% of cases.
Discussion
We evaluated the incidence of CHD with its determinantstering pattern of Hcy and MetS components. We questioned the
extent by which Hcy measurement could assist in the prediction
and prevention of a CHD event, beyond the capability of MetS and
+HHcy (categorical model) +Hcy (continuous model)
1.61 (1.30–2.00)* 1.63 (1.31–2.03)*
1.89 (1.45–2.46)* NA
3.62 (2.38–5.50)* NA
NA 1.07 (1.05–1.09)*
. All models are adjusted for age, gender, body mass index, low-density lipoprotein
applicable.
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Table 5
Summary of the statistics evaluating the addition of Hcy to MetS.
Adjusted MetS (baseline model) +HHcy (categorical model) +Hcy (continuous model)
Model calibration, HL 2 (p-value) 13.27 (0.10) 10.56 (0.23) 12.63 (0.12)
Model complexity, AIC 2936.38 2914.55 2938.21
Model complexity, BIC 2989.83 2974.68 2998.34
Likelihood ratio test, p-value <0.001 0.680
AUC 0.853 (0.839–0.867) 0.855 (0.841–0.869) 0.858 (0.844–0.872)
Incremental AUC 0.002 0.005
IDI 0.005 0.009
NRI – overall (%) 47.3 49.0
NRI – intermediate risk (%) 21.6 28.1
All models are adjusted for age, gender, body mass index, low-density lipoprotein cholesterol, smoking, family history of coronary heart disease, interventions, and drugs.
MetS, metabolic syndrome; Hcy, homocysteine; HHcy, hyper-homocysteinemia. AIC and BIC, Akaike and Bayesian Information Criterion; measures of model complexity,
weighting the additional information of a model against its entropy; a lower value indicates an increased global ﬁt. AUC, Area under the curve using receiver operating
characteristic curve statistics;measures of discrimination; a higher value indicates better discrimination of events vs. non-events. IDI, integrateddiscrimination improvement.
NRI, net reclassiﬁcation improvement; measuring the percent of reclassiﬁed subjects, among events and non-events; a higher value indicates better implication of the added
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he calibration of the models was assessed using Hosmer–Lemeshow (HL) 2 statis
he TRFs. A recent study by Veeranna et al. [29], evaluated the addi-
ion of Hcy to TRFs in two American cohorts. In agreement with
ur results, Hcy was found to be an independent predictor of CHD.
he adjusted HR for hard CHD events (according to Hcy of ≥15)
qualed 2.00 and 2.53 in MESA (Multi Ethnic Study of Atheroscle-
osis) and NHANES (National Health And Nutrition Examination
urvey) cohorts, respectively. By contrast, we report HHcy as an
ndependent predictor of CHD in diabetic and non-diabetic West
sian sub-cohorts. They also indicated amaximumof 21.2% of indi-
iduals with intermediate risk who can be correctly reclassiﬁed
sing Hcy levels. In comparison, in this study, by adding Hcy to
RFs and MetS, the authors successfully reclassiﬁed 28.1% of the
ntermediate-risk group.
Previous studies unveiled the CHD–Hcy association in various
on-diabetic subgroups [30,31]. However, this prospective asso-
iation was not well studied in Asian populations. Some authors
ad questioned [32,33] and even denied the role of Hcy in CHD
rediction in the region [34]. This is the ﬁrst prospective report
egarding the associated hazard of HHcy in a West Asian popula-
ion. An increase in every unit of Hcywas independently associated
ith 7% increase in CHD risk. Similarly, a previous meta-analysis
uggested a 20–50% increase in the risk of CHD for every ﬁve-unit
ncrease in Hcy level [35]. It was proposed that plasma Hcy level
s an independent risk factor for CHD. In the current study, the
uthors described HHcy as a relatively stronger predictor of CHD
.62 (2.38–5.50). Even mild increase in Hcy level (≥10) is associ-
ted with a 1.89-fold increased risk of CHD. Only a limited number
f prior studies have indicated the increased risk of CHD and CHD
ortality in HHcy diabetic patients [36].
CHD prevention in high-risk patients had been validated
horoughly [5,37]. Besides traditional treatments, Hcy-lowering
herapies were identiﬁed as strategies in preventing CHD events
15], knowing that folate and vitamin B supplementation can
educe the Hcy level [38]. However, recent investigations failed to
emonstrate the efﬁcacy of Hcy-lowering therapies in preventing
HD events in healthy individuals [16]. We suggest that the miss-
ng link lies in patient selection. Those who will be reclassiﬁed in
igher-risk groups due to an elevated Hcy level are the subgroup
hatwould beneﬁt fromHcy-lowering therapies. Nevertheless, fur-
her clinical trials should elucidate this issue.
Both Hcy and MetS have been allied to a number of metabolic
bnormalities [39]. Insulin resistance had been proposed as the
ain regulator of HHcy [40]. Even Hcy-lowering therapies were
hown to reduce insulin resistance [41]. In fact, there has been a
ight connectionbetween insulin resistance, endothelial injury, and>0.01).
HHcy, especially in diabetic subjects [39,42]. Nevertheless, the rela-
tion between Hcy and either MetS [43,44] or its components is a
matter of debate [18,45]. Even if related, it is not clearly understood
whether an increased Hcy level in subjects with MetS will add to
the risk of CHD [19]. The authors revealed that the factor that links
MetS to CHD is the factor through which Hcy is linked to MetS. In
other words, we contradict the idea that leaves no common mech-
anism for MetS and HHcy [17]. In the present study, Hcy and MetS
interacted as hazards and risk factors for CHD. Hcy added to the
predictive value of MetS and TRFs by reclassifying almost 50% of
the population. We insist that the presence of MetS should be con-
sidered when using Hcy for the prediction of an incident CHD [19].
We found metabolic abnormalities to be more prevalent in sub-
jects with higher serum Hcy levels. Hcy was correlated with MetS
components, especially through SBP. As a prior study suggests,
Hcy and SBP load on the same factor, which had the greatest pre-
dictability for CHD [46]. HHcy has been correlated to other MetS
components including insulin resistance, obesity, and waist cir-
cumference as well [47]. Our result is in agreement with clustering
of Hcy with MetS components, including waist circumference and
HOMA-IR.
Most of our current understanding of the CHD risk factors is
derived from studies on Caucasians of European origin. However,
it is well recognized that the ethnicity has a remarkable modu-
lating effect on the CHD risk factors effect [48]. Speciﬁcally, Asian
populations are recognized to be more susceptible to the adverse
effects from certain risk factors including abdominal obesity and
otherMetS components [20,49]. Call for studies assessing the effect
of ethnic differences on CHD risk factors has been made [48].
Various studies have revealed MetS–CHD association in Middle-
Eastern populations [12,49]. However, the Hcy–MetS relation in
West Asian populations remains a topic to be studied. Regard-
ing the role of ethnicity in Hcy–CHD association, it was reported
that HHcy is associated with an approximate 2-fold increase in the
CHD risk regardless of ethnicity [50]. Moreover, it was proposed
that ethnicity has no role in modifying the effect of Hcy-lowering
therapies despite nutritional and genetic differences [51]. Recent
studies have evaluated this issue among South Asians. They sug-
gested thatdietary factorsmayaffect theHcy–CHDassociation [52].
On the other side, contradicting results have pointed to ethnicity
as a determinant of serum Hcy [53]. In all, what is mainly accepted
is that the role of Hcy–CHD association remains to be closely clar-
iﬁed, especially with regard to the insulin resistance status [54].
Our study reports a close correlation between Hcy and MetS com-
ponents.
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The additional reclassiﬁcation power of Hcy was notable in
ur study. In comparison, other additional markers have provided
ower reclassiﬁcation improvements [6,9]. For instance, the calcu-
ated NRI was 9.35% for MetS components [55], 25% for coronary
rtery calciﬁcation [56], andup to 13.8% for a panel of geneticmark-
rs [57]. In the same line with a previous study, we emphasize the
emarkable beneﬁts of assessingHcy [29]. As an implication, testing
cy can help us in clinical decision making. Further studies includ-
ng economic evaluations are mandated to elucidate the feasibility
f Hcy testing in preventing CHD events.
imitations
One limitation of our study is the fact that our sample size was
ot be large enough to stratify our analyses for all different sub-
ypes of events without losing the statistical power adopted in
ur study. Interval gaps and time differences among the assumed
ntervals of entries and events are one of the shortcomings of
pen cohort studies. We tried to overcome that by more frequent
isits/follow-ups. We used adjudicated CHD events as the outcome
f our study. However, considering more robust (though complex)
rocedures including prospective changes in echocardiographic
arameters, will add valuable information to our current research
aps in the ﬁeld.
onclusion
Serum Hcy level is correlated to MetS components, especially
o SBP. The factor linking MetS to CHD is the same factor through
hich Hcy is linked to MetS. Hcy and MetS interacted as hazards
or CHD. Hcy successfully clustered with MetS components in pre-
icting CHD. Hcy added to the predictive value of MetS and TRFs in
redicting a CHD event by reclassifying around 50% of the at-risk
opulation.
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